Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.K. (FTSE) Healthcare Sector Analysis

UpdatedJul 02, 2026
DataAggregated Company Financials
Companies85
  • 7D-0.4%
  • 3M-8.8%
  • 1Y25.1%
  • YTD1.2%

Over the last 7 days, the Healthcare industry has remained flat. As for the the longer term, the industry is up 25% over the past 12 months. As for the next few years, earnings are expected to grow by 11% per annum.

Sector Valuation and Performance

Has the U.K. Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 03 Jul 2026UK£351.0bUK£103.7bUK£16.2b26.6x21.6x3.4x
Sun, 31 May 2026UK£347.6bUK£102.9bUK£16.1b27.2x21.6x3.4x
Tue, 28 Apr 2026UK£357.2bUK£101.3bUK£16.0b22.4x22.4x3.5x
Thu, 26 Mar 2026UK£360.4bUK£101.9bUK£16.1b22x22.3x3.5x
Sat, 21 Feb 2026UK£393.6bUK£101.0bUK£15.8b24.8x24.9x3.9x
Mon, 19 Jan 2026UK£354.2bUK£100.5bUK£15.0b25.4x23.6x3.5x
Wed, 17 Dec 2025UK£344.0bUK£100.3bUK£15.0b22.6x23x3.4x
Fri, 14 Nov 2025UK£346.2bUK£101.1bUK£15.1b24.5x22.9x3.4x
Sun, 12 Oct 2025UK£325.9bUK£98.8bUK£12.1b27.8x26.9x3.3x
Tue, 09 Sep 2025UK£312.8bUK£100.6bUK£12.0b29.5x26x3.1x
Thu, 07 Aug 2025UK£293.9bUK£101.2bUK£11.8b29.7x25x2.9x
Sat, 05 Jul 2025UK£281.7bUK£96.4bUK£10.7b32.2x26.3x2.9x
Mon, 02 Jun 2025UK£295.2bUK£97.1bUK£10.8b28.8x27.4x3x
Wed, 30 Apr 2025UK£285.2bUK£97.4bUK£10.2b28.4x28.1x2.9x
Fri, 28 Mar 2025UK£298.2bUK£98.4bUK£9.6b27.2x30.9x3x
Sun, 23 Feb 2025UK£306.2bUK£99.3bUK£9.3b29.3x32.9x3.1x
Tue, 21 Jan 2025UK£253.5bUK£87.1bUK£7.8b30.7x32.7x2.9x
Thu, 19 Dec 2024UK£244.3bUK£85.5bUK£7.6b30x32.2x2.9x
Sat, 16 Nov 2024UK£237.3bUK£85.8bUK£7.6b24.7x31.1x2.8x
Mon, 14 Oct 2024UK£273.8bUK£82.6bUK£8.9b28.6x30.8x3.3x
Wed, 11 Sep 2024UK£292.6bUK£82.3bUK£8.9b32.9x33x3.6x
Fri, 09 Aug 2024UK£291.6bUK£83.4bUK£9.0b33.1x32.5x3.5x
Sun, 07 Jul 2024UK£279.0bUK£81.3bUK£9.4b31.2x29.8x3.4x
Tue, 04 Jun 2024UK£287.4bUK£81.4bUK£9.4b31.3x30.7x3.5x
Thu, 02 May 2024UK£288.2bUK£82.5bUK£9.4b31.6x30.6x3.5x
Sat, 30 Mar 2024UK£268.5bUK£81.1bUK£9.6b34x27.9x3.3x
Mon, 26 Feb 2024UK£260.8bUK£80.5bUK£9.4b38.5x27.6x3.2x
Wed, 24 Jan 2024UK£271.8bUK£84.1bUK£10.6b39x25.5x3.2x
Fri, 22 Dec 2023UK£267.8bUK£84.1bUK£10.7b40.4x25.1x3.2x
Sun, 19 Nov 2023UK£261.8bUK£84.9bUK£10.8b41.5x24.3x3.1x
Tue, 17 Oct 2023UK£277.7bUK£85.9bUK£10.3b40.2x27x3.2x
Thu, 14 Sep 2023UK£272.3bUK£84.8bUK£10.2b40.2x26.7x3.2x
Sat, 12 Aug 2023UK£276.7bUK£84.0bUK£10.2b41.1x27.2x3.3x
Mon, 10 Jul 2023UK£258.2bUK£82.2bUK£7.8b42.7x32.9x3.1x
Price to Earnings Ratio

32.9x


Total Market Cap: UK£258.2bTotal Earnings: UK£7.8bTotal Revenue: UK£82.2bTotal Market Cap vs Earnings and Revenue0%0%0%
U.K. Healthcare Sector Price to Earnings3Y Average 27.5x202420252026
Current Industry PE
  • Investors are pessimistic on the British Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 21.6x which is lower than its 3-year average PE of 27.6x.
  • The industry is trading close to its 3-year average PS ratio of 3.3x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 27% per year over the last three years.
  • Revenues for these companies have grown 8.1% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.K. Healthcare sector?

GB Market0.24%
Healthcare-0.43%
Life Sciences10.48%
Healthtech6.83%
Biotech1.53%
Pharma-0.46%
Healthcare Services-0.48%
Medical Equipment-1.43%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio.
    • Analysts are expecting annual earnings growth of 16.5%, which is lower than the prior year's growth of 51.1% per year.
Forecasted Growth
  • Analysts are most optimistic on the Life Sciences industry, expecting annual earnings growth of 57% over the next 5 years.
  • In contrast, the Pharma industry is expected to see its earnings grow by 10% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
AZN AstraZenecaUK£145.383.4%
+UK£7.4b		42.5%PE29x
HLN HaleonUK£3.603.5%
+UK£1.1b		-3.4%PE19.1x
GSK GSKUK£20.041.0%
+UK£816.9m		43.8%PE13.7x
CTEC Convatec GroupUK£2.203.7%
+UK£152.4m		-17.3%PE32.7x
HCM HUTCHMED (China)UK£1.7510.2%
+UK£139.7m		-23.9%PE4.4x

Latest News

OBD
UK£0.0009
Oxford BioDynamics
7D
-47.7%
1Y
-70.0%
PRTC
UK£1.24
PureTech Health
7D
-5.6%
1Y
-4.0%
HCM
UK£1.75
HUTCHMED (China)
7D
10.2%
1Y
-23.9%
HLN
UK£3.60
Haleon
7D
3.5%
1Y
-3.4%
Narrative Update • Jul 01

HLN: Lower Forward P E Assumptions Will Pressure Future Share Price

Haleon’s analyst price target has been trimmed by £0.10 to £3.15, as analysts factor in a slightly lower assumed future P/E, alongside recent Street moves that have reduced targets and, in one case, shifted the stock to a Neutral stance. Analyst Commentary Recent Street research on Haleon points to a more cautious tone, with several bearish analysts trimming price targets and reassessing risk around valuation, execution and future growth assumptions.
AZN
UK£145.38
AstraZeneca
7D
3.4%
1Y
42.5%
SN.
UK£11.27
Smith & Nephew
7D
-1.7%
1Y
1.8%
GSK
UK£20.04
GSK
7D
1.0%
1Y
43.8%
SAR
UK£0.21
Sareum Holdings
7D
-8.7%
1Y
6.3%
HIK
UK£15.54
Hikma Pharmaceuticals
7D
1.6%
1Y
-21.8%
CVSG
UK£12.35
CVS Group
7D
5.3%
1Y
-0.2%
Narrative Update • Jun 24

CVSG: Share Buyback Momentum Will Support Future Upside Potential

Analysts have kept their fair value estimate for CVS Group steady at £16.40, with small adjustments to assumptions such as the discount rate and future P/E leading to only a marginal change in the overall price target narrative. What’s in the News for CVS Group CVS Group commenced a share repurchase program on May 26, 2026, committing up to £50 million to buy back its shares.
GNS
UK£23.12
Genus
7D
8.4%
1Y
7.3%
Narrative Update • Jun 22

GNS: Margin Discipline And New Bank Coverage Will Support Medium Term Upside

Analysts have maintained their fair value estimate for Genus at £37.00, with recent research indicating that this figure represents a balance between differing new views from JPMorgan and BNP Paribas on the stock's prospects. Analyst Commentary Recent coverage of Genus reflects a split in opinion, with some bullish analysts highlighting upside potential while others strike a more cautious, neutral tone.
CTEC
UK£2.20
Convatec Group
7D
3.7%
1Y
-17.3%
Narrative Update • Jun 22

CTEC: Advanced Wound Care Pipeline Will Support Future Rerating Potential

Convatec Group's analyst price targets have been trimmed, with recent moves such as Citi cutting its view to £2.30 from £2.50 and JPMorgan to £2.94 from £3.07, highlighting a more cautious stance even as analysts point to steady assumptions on fair value, discount rate, revenue growth, profit margin and future P/E in their updated models. Analyst Commentary Recent research on Convatec Group points to a mixed but engaged view from the Street, with some analysts trimming price targets while others make supportive adjustments that reflect differing opinions on valuation, execution and growth potential.
BVXP
UK£16.00
Bioventix
7D
-4.5%
1Y
-41.8%
AGY
UK£0.065
Allergy Therapeutics
7D
-7.7%
1Y
-19.3%
AVCT
UK£0.72
Avacta Group
7D
-4.6%
1Y
126.6%
SCLP
UK£0.15
Scancell Holdings
7D
-21.1%
1Y
57.9%